ONI is a technology company.
ONI specializes in super-resolution microscopy, providing advanced imaging solutions for various biological applications.
ONI has raised $75.0M across 1 funding round.
ONI has raised $75.0M in total across 1 funding round.
ONI has raised $75.0M in total across 1 funding round.
ONI's investors include Alumni Ventures, Anderson Angels, ARCH Venture Partners, Stuart Peterson, Artis Ventures (AV), Canaan Partners, Genoa Ventures, Illumina Ventures, Madrona Ventures, Modern Venture Partners, Northpond Ventures, Paladin Capital Group.
ONI is a life sciences tools company that develops accessible super-resolution microscopy technology to accelerate scientific discovery and fight disease by enabling researchers to visualize microscopic details of life.[1][2][3] Its flagship product, the Nanoimager, is the world's first benchtop super-resolution microscope, supporting techniques like dSTORM, PALM, smFRET, single-particle tracking, and confocal imaging, while serving academic labs, clinicians, pharmaceutical companies, and biotech firms.[2][3] ONI solves the problem of complex, expensive super-resolution tools previously limited to elite labs by offering benchtop usability, intuitive software, automated workflows, and consumables that enhance reproducibility, speed, and affordability.[1][2][3][4]
The company targets challenges in therapeutic discovery, such as understanding molecular mechanisms, antibody drug actions, extracellular vesicles (EVs), and lipid nanoparticles, with customers including leading institutions like the Universities of Oxford, Cambridge, and Harvard.[2][3] Growth momentum includes early recognition as a 2018 FastTrack100 Disruptor and IOP Best Business Startup, global adoption, and expansions into EV and lipid nanoparticle research markets as of 2024.[2]
ONI originated as a spin-out from the University of Oxford, incorporated in February 2016 and commencing trading in May 2016 with a focus on the Nanoimager.[1] Rooted in Nobel Prize-winning super-resolution microscopy research, the idea emerged to democratize this elite technology for broader use beyond specialized labs with vast budgets.[4] Early traction came swiftly: by 2018, ONI earned spots on FastTrack100's 10 Disruptors to Watch list and won Best Business Startup at the IOP Awards, alongside securing customers in top global labs.[2] This Oxford heritage and rapid accolades humanize ONI as a mission-driven innovator bridging academia and industry to simplify super-resolution workflows.[1][3]
ONI rides the wave of advancing therapeutic discovery and precision medicine, where super-resolution microscopy unlocks subcellular details critical for drug development, such as protein complexes, tumor microenvironments, and nanoparticle delivery systems.[2][3][5] Timing aligns with surging demand for accessible biotech tools amid AI-driven analysis and EV research booms, as seen in ONI's 2024 expansions into lipid nanoparticles and single-particle EV imaging.[2] Market forces like rising pharma R&D investments and the need for reproducible, cost-effective imaging favor ONI, positioning it to influence the ecosystem by empowering non-elite labs and accelerating breakthroughs in molecular biology and disease fighting.[1][3][4]
ONI's trajectory points toward deeper integration of AI-enhanced imaging, building on webinars like AI-Driven EV Analysis and partnerships for complex workflows, to dominate accessible super-res tools.[2][5] Trends in spatial biology, NGS automation, and nanoparticle therapeutics will shape its path, potentially expanding consumables and software for broader therapeutic applications.[2][3][5] Its influence may evolve from pioneer to ecosystem enabler, further democratizing microscopy and fueling discoveries that transform medicine—echoing its Oxford roots in making elite science universal.[1][4]
ONI has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $75.0M Series B | Alumni Ventures, Anderson Angels, ARCH Venture Partners, Stuart Peterson, Artis Ventures (AV), Canaan Partners, Genoa Ventures, Illumina Ventures, Madrona Ventures, Modern Venture Partners, Northpond Ventures, Paladin Capital Group, Razor's Edge Ventures, Rebel Fund, Section 32, Shasta Ventures, Sierra Ventures, Vertical Venture Partners, Daniel Rothman |